The History of Alzheimer’s Disease

James M. Ellison, MD, MPH

Swank Center for Memory Care and Geriatric Consultation, ChristianaCare

  • Expert Advice
Published on:
Man silhouette made of points of light, abstract painting.

Learn about how Alzheimer’s disease was discovered, the search for the cause of this brain disease, and the future of Alzheimer’s treatment.

Auguste Deter

When Alois Alzheimer met Auguste Deter in 1901, he could not have suspected that her sad story would make his name a household word throughout the world. Dr. Alzheimer was a young psychiatrist in his late 30s, a hard-working clinician committed to understanding the relationship between brain disease and mental illness. Following the death of his wife earlier that year, he had buried himself in his clinical work, caring for psychiatric patients at the Community Hospital for Mental and Epileptic Patients in Frankfurt, Germany.

Auguste Deter (whom we would learn about as “Auguste D”) was only 50 years old when her husband noticed her increasing memory problems. She soon became more fearful, paranoid, and aggressive, making it necessary to admit her to the psychiatric hospital at age 51. She remained an inpatient there until her death in 1906, although by then she was no longer under Dr. Alzheimer’s care. He had since moved on to a research position at the Munich Hospital under the leadership of Dr. Emil Kraepelin, one of the most influential psychiatrists of his era.

Alzheimer’s former boss from Frankfurt, Dr. Emil Sioli, informed Dr. Alzheimer of his former patient’s death. He sent her brain material to Alzheimer, who examined Ms. Deter’s brain microscopically using new stains that revealed the presence of what we now call amyloid plaques and neurofibrillary tangles. Though it seems odd now, Alzheimer’s initial 1906 presentation linking this specific brain pathology to a clinical syndrome was met with limited enthusiasm by his peers.

The First Use of “Alzheimer’s Disease”

Alzheimer later published his descriptions of several similar patients in 1909 and Kraepelin included Ms. Deter’s case in the 1910 edition of his widely respected psychiatry textbook. It was Kraepelin who named this dementia after his junior colleague.

Auguste Deter was not an elderly woman at the onset of her illness, and Alzheimer’s disease was therefore regarded as a “presenile dementia” to distinguish it from the familiar “senile dementia,” thought to result from aging-related vascular disease. Further investigation, however, showed that plaques and tangles were present in the brains of the majority of older adults with symptoms of dementia.

In the late 1960s, the British psychiatrists Tomlinson and Roth described the importance of these plaques in older adults, and in 1970 Dr. Roth questioned the meaningfulness of the age criterion that distinguished Alzheimer's disease from “senile dementia of the Alzheimer’s type.”

The Most Common Form of Dementia

The American neurologist Robert Katzman suggested in 1976 that we should do away with the age distinction that separated pre-senile from senile dementia of the Alzheimer’s type and by the early 1980s, Alzheimer's disease was widely recognized as the most common cause of dementia in older adults.

The Search for the Cause

The “Cholinergic Hypothesis”

The search for Alzheimer's causes began with Dr. Alzheimer and continues today in full force. In the late 1970s, researchers described a “cholinergic hypothesis” of Alzheimer's disease. This theory attributed disease symptoms to a deficit of the neurotransmitter acetylcholine, a small chemical messenger essential for proper memory function. This theory encouraged the testing of medications that increased brain levels of acetylcholine by either increasing its production or blocking its destruction. One class of these experimental medications, the cholinesterase inhibitors, was approved by the FDA and remains in common use today. Donepezil, rivastigmine, and galantamine are examples of cholinesterase inhibitors.

We can thank the cholinergic hypothesis for providing us with medicine that has mild symptom-reducing effects. Unfortunately, this class of medication has no real effect on disease progression. Researchers now consider the changes in the cholinergic system to be downstream of more basic disease mechanisms.

Memantine, the other FDA-approved medication for Alzheimer's disease treatment, is thought to work differently, by stabilizing functioning of the glutamate system. Like the cholinesterase inhibitors, memantine is a symptom-alleviating, rather than disease-modifying, medication.

The “Amyloid Cascade”

In 1984, the identification of the beta-amyloid protein in the blood vessels of patients with Down syndrome and Alzheimer's disease suggested that the 21st chromosome (present in an extra copy in people with Down syndrome), might hold clues to understanding the pathology of Alzheimer's.

This proved true when beta amyloid was identified in 1987 as an important component of senile plaques and was linked to a gene located on chromosome 21. Soon after, in the early 1990s, the discovery of mutations that promoted excessive production of beta-amyloid protein with Alzheimer's disease added evidence to what became the “amyloid cascade” hypothesis, which is the theory that Alzheimer's pathology results from accumulation of amyloid plaques in the brain leading to an inflammatory response and brain cell destruction.  These mutations, each in their own way, raised levels of beta amyloid and increased the risk for developing clinical Alzheimer's.

A Protein Called Tau

Much, but not all, of the international Alzheimer's disease research effort in recent years has been driven by the amyloid cascade hypothesis. Competing or complementary theories, however, have also urged consideration of the importance of tau protein abnormalities, which lead to the formation of neurofibrillary tangles (the insoluble twisted fibers found inside the brain's cells). The tau protein forms part of a structure called a microtubule, which helps transport nutrients and other important substances from one part of the nerve cell to another. In Alzheimer's disease, however, the tau protein is abnormal and the microtubule structures collapse.

Pathological changes in tau protein, as supporters of the tau theory point out, closely parallel the clinical changes that occur later in Alzheimer's.

Other Research Avenues

Other researchers have focused on the importance of lifestyle factors, changes in the blood-brain barrier, improper metabolism of metals such as copper or iron or zinc, systemic inflammation, or inflammation-inducing infections with bacteria or fungi as potential pathways to the development of Alzheimer's disease.

Redefining Alzheimer’s

In 2011, Alzheimer's clinical detection and treatment research took a major step forward when a joint committee of experts reviewed earlier studies and reached a groundbreaking conclusion .

Based on decades of evidence with biomarkers and neuroimaging, the experts on this committee recommended that we redefine what we consider Alzheimer's disease. No longer should it be regarded as simply a clinical syndrome of dementia, but instead it should be understood as a pathological process that develops into a clinical disease over the course of decades.

Before cognitive decline steals away a person’s independence, the disease must simmer during an initial, asymptomatic clinical phase that can persist for years. During this period, amyloid accumulation can be demonstrated using advanced neuroimaging techniques or examination of cerebrospinal fluid.

In this new model of Alzheimer's, symptoms begin to appear during the second, mildly symptomatic pre-dementia stage which is called mild cognitive impairment or mild neurocognitive disorder. During this phase, the pathology continues to progress, but clinical symptoms remain limited. Performance of more complex tasks is affected, but general independence is preserved.

Only in the third phase, the phase of dementia (now called “major neurocognitive disorder”) do we see the characteristic independence-destroying changes in cognitive and behavioral functioning.

Early Detection

This reframing of the nature of Alzheimer's, focusing on its pathology rather than its symptoms, has nurtured research into techniques for earlier detection and promoted the idea that intervention in the earliest stages, even before disease symptoms are present, may offer more hope than efforts to reverse the destructive effects of the disease’s third stage.


Furthermore, the recognition of Alzheimer's pre-symptomatic phase encourages greater attention to preventive interventions such as management of chronic medical illnesses that impact brain health, attention to brain-healthy nutrition, increased aerobic activity, restorative sleep, and other brain healthy lifestyle interventions.

A Brighter Era

Although the number of people with Alzheimer's continues to increase daily, our time is a brighter era in the history of this and other dementias. More than 100 new medications are now being tested and many nonpharmacologic interventions, some of them preventive, are being explored. Even if the damage of later stages of Alzheimer's are impossible to cure or reverse, current investigations offer the hope of arresting or slowing the disease’s effects – and perhaps identifying and preventing progression at an earlier, even asymptomatic stage.

As Yogi Berra is supposed to have said, “The future ain’t what it used to be.”  And with respect to dementia treatment, we can hope the future will bring greater help for people with dementia and those who care for them.

About the author

Headshot of Dr. James Ellison

James M. Ellison, MD, MPH

Swank Center for Memory Care and Geriatric Consultation, ChristianaCare

James Ellison, MD received his medical degree from UCSF in 1978 and trained in psychiatry at the Massachusetts General Hospital (1979-1982).

About BrightFocus Foundation

BrightFocus Foundation is a premier global nonprofit funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. Through its flagship research programs — Alzheimer’s Disease Research, National Glaucoma Research, and Macular Degeneration Research — the Foundation has awarded nearly $290 million in groundbreaking research funding over the past 50 years and shares the latest research findings, expert information, and resources to empower the millions impacted by these devastating diseases. Learn more at   


The information provided in this section is a public service of BrightFocus Foundation, should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we make efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research.     

Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.  

Help find a cure

Donate to help end Alzheimer's Disease

I would like to donate

Stay in touch

Receive Alzheimer's Disease research updates and inspiring stories